Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials.

Bowling, Gartrell C; Swargaloganathan, Piragash; Heintz, Carly; Madan, Ravi A; Eldhose, Binil; Dobi, Albert; Chesnut, Gregory T

Bowling, Gartrell C; Swargaloganathan, Piragash; Heintz, Carly; Madan, Ravi A; Eldhose, Binil; Dobi, Albert; Chesnut, Gregory T.

Afiliação

Bowling GC; School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA.
Swargaloganathan P; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA.
Heintz C; School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA.
Madan RA; School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA.
Eldhose B; Genitourinary Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Dobi A; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA.
Chesnut GT; Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 20817, USA.

Cancers (Basel) ; 15(19)2023 Oct 09.

Article em En | MEDLINE | ID: mdl-37835597

Palavras-chave

CRPC; PARP inhibitors; Poly ADP-ribose polymerase (PARP); niraparib; olaparib; prostate cancer; rucaparib; talazoparib; veliparib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Ano de publicação: 2023 Tipo de documento: Article